Advertising Claims Enforcement Roundup: OmegaFlex, Eyebright, Kyrobak
This article was originally published in The Tan Sheet
Executive Summary
OmegaFlex short on claims substantiation; UK dims Eyebright and pulls plug on pain device claims
You may also be interested in...
UK Supplement Firm’s Advertising Quality Control Misses Bogus Claim
UK retailer The Hut.com pulled unauthorized claims for its Myprotein L-Glutamine product during an ASA review, but the agency investigated and found the firm in violation of UK advertising regs.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.